Recent Finacing
Recent Raise
Adagio Therapeutics develops engineered, broadly neutralizing monoclonal antibodies targeting a conserved coronavirus spike epitope; lead candidate ADG20 is optimized for potency, extended half-life, IM dosing, and clinical trials.
